10-Q: Arbutus Biopharma Swings to Profit Amid Restructuring

Arbutus Biopharma reported a significant revenue increase and a swing to net income in Q2 2025, driven by a terminated partnership and substantial cost reductions, while advancing its cHBV pipeline and patent litigation.

Summary

• Reported net income of $2.5 million for the three months ended June 30, 2025, a significant improvement from a net loss of $19.8 million in the same period of 2024.
• Total revenue increased to $10.7 million for Q2 2025, up from $1.7 million in Q2 2024, primarily due to the recognition of $9.6 million in previously deferred revenue from the terminated Qilu partnership.
• Operating expenses decreased substantially to $9.3 million for Q2 2025, down from $23.3 million in Q2 2024, driven by significant reductions in research and development and general and administrative expenses.
• Research and development expenses decreased by $10.1 million for Q2 2025 compared to Q2 2024, reflecting a strategic decision to cease discovery efforts, discontinue the IM-PROVE III clinical trial, and implement workforce reductions.
• General and administrative expenses decreased by $4.2 million for Q2 2025 compared to Q2 2024, mainly due to reduced employee compensation and litigation-related legal fees.
• Incurred $12.4 million in one-time restructuring charges in Q1 2025, with an additional $0.2 million in Q2 2025, related to a 57% workforce reduction, exiting corporate headquarters, and discontinuing in-house scientific research.
• Ended Q2 2025 with $98.1 million in cash, cash equivalents, and marketable securities, and no outstanding debt.
• Regained global rights for imdusiran (AB-729) following the mutual termination of the strategic partnership with Qilu Pharmaceutical Co., Ltd. in June 2025.
• Advanced its cHBV pipeline with imdusiran and AB-101; imdusiran showed functional cure rates of 50% (3/6) in a specific patient subgroup in IM-PROVE I and 25% (2/8) in a specific subgroup in IM-PROVE II.
• Ongoing patent infringement lawsuits against Moderna and Pfizer/BioNTech for the unlicensed use of its patented LNP delivery technology in their COVID-19 mRNA-LNP vaccines.

Sentiment

Score: 7

Explanation: The company demonstrated a significant financial turnaround with a swing to net income and substantial cost reductions. Clinical trial data for imdusiran shows promising functional cure rates, and the company regained global rights for this key asset. However, ongoing high-stakes patent litigation and the stated need for future capital raise introduce considerable uncertainty and risk, tempering overall sentiment.

Positives

• Achieved net income of $2.5 million in Q2 2025, a significant turnaround from a $19.8 million net loss in Q2 2024.
• Total revenue increased by $9.0 million in Q2 2025, primarily due to the recognition of $9.6 million in deferred revenue from the Qilu partnership termination.
• Operating expenses decreased by $14.1 million in Q2 2025, reflecting successful cost management and strategic streamlining.
• Reduced net cash used in operating activities to $29.1 million for the six months ended June 30, 2025, down from $33.8 million in the prior year period.
• Regained global rights for imdusiran, a key proprietary asset, after terminating the Qilu partnership.
• Imdusiran clinical trials (IM-PROVE I and II) demonstrated functional cure rates of 50% (3/6) and 25% (2/8) respectively in specific patient cohorts with baseline HBsAg levels less than 1000 IU/mL.
• AB-101, an oral PD-L1 inhibitor, was generally well-tolerated with evidence of high receptor occupancy in Phase 1a/1b clinical trials.
• Maintained a strong liquidity position with $98.1 million in cash, cash equivalents, and marketable securities as of June 30, 2025, and no outstanding debt.
• Launched a new Scientific Advisory Board with globally-recognized leaders in cHBV treatment to advise on pipeline strategy.

Negatives

• Incurred significant restructuring costs of $12.4 million in Q1 2025 and an additional $0.2 million in Q2 2025 due to workforce reductions and exiting corporate headquarters.
• Investments in marketable securities, current, decreased from $86.3 million at December 31, 2024, to $60.7 million at June 30, 2025.
• Non-cash royalty revenue from ONPATTRO decreased in 2025 periods compared to 2024 periods due to lower sales.
• Interest income decreased due to lower average cash and investment balances and a general decrease in market interest rates.

Risks

• Uncertainty regarding the outcome and timing of patent infringement lawsuits against Moderna and Pfizer/BioNTech, which could significantly impact future revenue and financial condition.
• The need for substantial additional funds to continue the active development of pipeline products and technologies, with no assurance that funding will be available on acceptable terms.
• Potential for delays in the development of product candidates due to preclinical and clinical findings, which could increase costs and postpone commercialization.
• Reliance on the ability to attract and retain development or commercialization partners, and their effectiveness in advancing product candidates.
• Exposure to competing products, product candidates, and technological and market developments in the biopharmaceutical industry.

Future Outlook

We expect to significantly reduce our net cash burn in 2025 compared to 2024 due to organizational changes and ongoing cost management efforts. Substantial additional funds will be required to continue the active development of pipeline products and technologies, with funding needs varying based on factors like patent litigation costs, revenue from collaborations, milestone payments, and clinical trial progress.

Management Comments

• Our strategy is focused on maximizing opportunities for our cHBV development programs and our in-house developed LNP delivery technology.
• We remain committed to taking all legal actions necessary to defend and protect our intellectual property.
• By providing a functional cure for patients with cHBV, we aim to prevent complications of disease progression, to decrease HBV burden by minimizing patient stigma and to address the need for finite and more efficacious HBV treatments that further improve long-term outcomes and reduce associated healthcare costs.

Industry Context

The biopharmaceutical industry is highly competitive, particularly in infectious diseases like chronic hepatitis B (cHBV), where the goal is to achieve a functional cure. The development of effective drug delivery systems, such as Lipid Nanoparticle (LNP) technology, has been critical for the success of mRNA-based therapeutics, as demonstrated by COVID-19 vaccines. This has led to increased intellectual property disputes over foundational technologies. Companies in this space often rely on a combination of internal R&D, strategic collaborations, and robust intellectual property defense to advance their pipelines and secure market position.

Comparison to Industry Standards

• Imdusiran's functional cure rates of 50% (3/6) in HBeAg negative patients with baseline HBsAg <1000 IU/mL in IM-PROVE I and 25% (2/8) in a similar cohort in IM-PROVE II are presented as significant, with the 50% rate noted as the 'highest functional cure rates in cHBV patients to date' in combination with IFN and NA therapy, suggesting a strong performance relative to existing literature and treatments.
• AB-101 is differentiated from monoclonal antibody checkpoint inhibitors like durvalumab (anti-PD-L1) and nivolumab (anti-PD-1) by being liver-centric, having a shorter duration of effect in preclinical models, and a novel mechanism of action involving PD-L1 protein dimerization, internalization, and degradation, potentially offering dosing and safety advantages over systemic antibody therapies.

Management Changes

Corporate Governance

Legal Proceedings

• U.S. patent infringement lawsuit against Moderna, Inc. and an affiliate, seeking damages for infringement of multiple U.S. patents related to LNP technology in their COVID-19 vaccine (MRNA-1273). The summary judgment phase began in July 2025, with a jury trial scheduled for March 2026.
• Five international patent infringement lawsuits filed against Moderna in March 2025 across 30 countries, seeking monetary relief and injunctions for LNP technology use in COVID-19 and RSV vaccines. First major hearings are expected in the first half of calendar year 2026.
• U.S. patent infringement lawsuit against Pfizer Inc. and BioNTech SE, seeking damages for infringement of multiple U.S. patents related to LNP technology in their COVID-19 mRNA-LNP vaccines. The claim construction hearing occurred in December 2024, with a ruling potentially in 2025.
• European Patent Office (EPO) oppositions by Moderna and Merck against Arbutus European patent EP 2279254 (the 254 Patent). The EPO upheld the patent in June 2024, but both parties appealed, with oral proceedings scheduled for January 2026.
• Moderna filed a revocation action on EPO patent EP 4 241 767 (the 767 patent) in April 2025, requesting its revocation.

Related Party Transactions

• Entered into an agreement on August 5, 2025, with Keith Manchester, M.D., a former Board member (until February 24, 2025), for consulting services regarding development strategy and hepatitis B programs. The agreement includes a grant of options to purchase 400,000 common shares.

Stakeholder Impact

• Shareholders: Potential for significant upside from successful patent litigation outcomes and clinical trial advancements, but also risk of dilution from future capital raises and ongoing litigation costs.
• Employees: Experienced significant workforce reductions (57% in Q1 2025, 40% in Q3 2024) as part of restructuring, impacting morale and job security.
• Customers/Patients: Continued development of imdusiran and AB-101 aims to provide a functional cure for chronic hepatitis B, potentially improving long-term outcomes and reducing healthcare costs for patients.
• Creditors: No outstanding debt as of June 30, 2025, indicating a healthy balance sheet from a debt perspective.
• Partners (e.g., Qilu): Termination of the Qilu partnership means the company regains global rights for imdusiran, potentially opening new collaboration opportunities but also shifting full development responsibility.

Next Steps

• Jury trial for the U.S. patent infringement lawsuit against Moderna is scheduled for March 2026.
• First major hearings in the five international lawsuits against Moderna are expected in the first half of calendar year 2026.
• The court's ruling in the claim construction hearing for the Pfizer/BioNTech lawsuit could potentially come in 2025.
• Oral proceedings for the appeal of the EPO's decision on the 254 Patent are scheduled for January 2026.
• Preparation of response to Moderna's opposition brief for the EPO patent EP 4 241 767 is ongoing.
• Part 3 of the AB-101-001 Phase 1a/1b clinical trial, evaluating repeat doses in cHBV patients, is ongoing.

Key Dates

Recommendation

The company has demonstrated a strong financial turnaround, swinging to net income and significantly reducing operating expenses, which is a positive indicator of improved financial management and strategic focus. The regaining of global rights for imdusiran and promising early clinical data for its cHBV programs offer long-term potential. However, the company's valuation remains heavily influenced by the highly uncertain and protracted patent infringement lawsuits against Moderna and Pfizer/BioNTech. While a favorable outcome could lead to substantial financial gains, the litigation process is lengthy and unpredictable. Furthermore, the company explicitly states the need for substantial additional funds for future development, which could lead to dilution. Given the improved financial health and clinical progress balanced against the significant legal and funding uncertainties, a 'hold' recommendation is appropriate for seasoned investors, awaiting clearer outcomes from the litigation and further clinical milestones before a stronger position can be taken.

Keywords

Biopharma, Hepatitis B, HBV, RNAi, LNP Technology, Patent Litigation, Moderna, Pfizer, BioNTech, Imdusiran, AB-729, AB-101, PD-L1 Inhibitor, Clinical Trials, SEC Filing, Biopharmaceutical, Infectious Disease